-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Program Covers Broad Spectrum of Topics in Thoracic Oncology
The chairs of WCLC 2023 say this year’s program offers something for everyone, including practice-changing clinical trial data and innovative basic science as well as presentations to address broader needs within the profession.
-
Make the Most of WCLC 2023: Mobile App Launches August 31
Whether you are attending in-person or virtually, the conference app will help you navigate the meeting and connect with your colleagues from around the globe.
-
Know Before You Go: Getting To—And Around—Singapore
Before you pack your bags, make sure you know everything you will need to get to the 2023 World Conference on Lung Cancer without delay.
-
Order Tickets for Special Events Today
As you plan your WCLC 2023 itinerary, don’t miss an important session on your list because you don’t have a ticket. Review the ticketed events schedule and be sure you have any tickets you will need.
-
Neoadjuvant Immunotherapy in NSCLC: A Window of Opportunity Not to Be Missed
Dr. Jamie Chaft says neoadjuvant chemoimmunotherapy offers thoracic oncologists an opportunity to cure more patients.
-
Adjuvant IO for Operable NSCLC: Where Does It Fit a Changing Landscape?
Dr. Mary O’Brien and colleagues say decision making around operable cases is becoming increasingly complex, making a multidisciplinary approach imperative.
-
Demystifying AI: How Will Artificial Intelligence Alter the Practice of Thoracic Oncology?
In Part 2 of their exploration of artificial intelligence, Dr. Raymond Mak and Fridolin Haugg reflect on the possibilities ahead for the diagnosis and treatment of lung cancer.
-
Inflammation’s Dark Symphony: Lung Cancer and Depression in Concert
Dr. Barbara Andersen’s research has shown depression severity is associated with prognostically poor inflammation in patients with non-small cell lung cancer.
-
In Brief for July 26, 2023
IASLC Hot Topic meeting to feature keynote address on resistance to immunotherapy by Dr. Drew Pardoll. Lung Cancer Research Foundation announces appointment of new executive director Aubrey Rhodes.
-
Demystifying AI: Current Insights on Artificial Intelligence in Thoracic Oncology
Dr. Raymond Mak and Fridolin Haugg delve into the artificial intelligence discussion with an overview of AI basics and a look at how AI is already influencing the lung cancer field.
View ILCN Archives
Provider Resources
Popular Articles